{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:15:35Z","timestamp":1790702135712,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1208\/s12248-021-00660-3","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T19:03:06Z","timestamp":1639162986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety Exposure\u2013Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma"],"prefix":"10.1208","volume":"24","author":[{"given":"Brian","family":"Hess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Alderuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"660_CR1","unstructured":"Sapkota S, Shaikh H. Non-Hodgkin lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [Updated 2020 Dec 14]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559328\/."},{"issue":"9","key":"660_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790\u20135. https:\/\/doi.org\/10.1002\/ajh.24086.","journal-title":"Am J Hematol"},{"issue":"Suppl 5","key":"660_CR3","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v83\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdw400.","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"660_CR4","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv62\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdx223.","journal-title":"Ann Oncol."},{"issue":"Suppl 5","key":"660_CR5","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116-25. https:\/\/doi.org\/10.1093\/annonc\/mdv304.","journal-title":"Ann Oncol"},{"key":"660_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/cmar.s34273","volume":"5","author":"MP Chao","year":"2013","unstructured":"Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin\u2019s lymphoma - novel and emerging therapies. Cancer Manag Res. 2013;5:251\u201369. https:\/\/doi.org\/10.2147\/cmar.s34273.","journal-title":"Cancer Manag Res"},{"issue":"14","key":"660_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","volume":"133","author":"C Casulo","year":"2019","unstructured":"Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133(14):1540\u20137. https:\/\/doi.org\/10.1182\/blood-2018-08-822148.","journal-title":"Blood"},{"issue":"23","key":"660_CR8","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study. J Clin Oncol. 2015;33(23):2516\u201322. https:\/\/doi.org\/10.1200\/jco.2014.59.7534.","journal-title":"J Clin Oncol"},{"issue":"1","key":"660_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22\u201332. https:\/\/doi.org\/10.1182\/blood-2014-05-577189.","journal-title":"Blood"},{"issue":"12","key":"660_CR10","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135. https:\/\/doi.org\/10.1182\/blood-2010-03-276246.","journal-title":"Blood"},{"issue":"2","key":"660_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/jco.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155\u201365. https:\/\/doi.org\/10.1200\/jco.19.00172.","journal-title":"J Clin Oncol"},{"issue":"7","key":"660_CR12","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/s2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511\u201322. https:\/\/doi.org\/10.1016\/s2352-3026(20)30120-4.","journal-title":"Lancet Haematol"},{"issue":"7","key":"660_CR13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/s1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388. https:\/\/doi.org\/10.1016\/s1470-2045(20)30225-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"660_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"26","key":"660_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"5","key":"660_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633\u201343. https:\/\/doi.org\/10.1111\/bjh.15412.","journal-title":"Br J Haematol"},{"issue":"1","key":"660_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https:\/\/doi.org\/10.1186\/2162-3619-1-36.","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"660_CR18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094\u2013105. https:\/\/doi.org\/10.1182\/blood-2017-10-813493.","journal-title":"Blood"},{"issue":"19","key":"660_CR19","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O\u2019Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634\u201345. https:\/\/doi.org\/10.1182\/blood.2020007512.","journal-title":"Blood"},{"issue":"23","key":"660_CR20","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1158\/1078-0432.ccr-19-0711","volume":"25","author":"BS Kahl","year":"2019","unstructured":"Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, et al. A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2019;25(23):6986\u201394. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-0711.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"660_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/s1470-2045(21)00139-x","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790\u2013800. https:\/\/doi.org\/10.1016\/s1470-2045(21)00139-x.","journal-title":"Lancet Oncol"},{"issue":"4","key":"660_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wics.1310","volume":"6","author":"SC Chow","year":"2014","unstructured":"Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat. 2014;6(4):304\u201312. https:\/\/doi.org\/10.1002\/wics.1310.","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"key":"660_CR23","unstructured":"ADC Therapeutics. Loncastuximab tesirine population PK report. ADC Therapeutics Inc.: 2020. Run 235."},{"issue":"27","key":"660_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/jco.2013.54.8800.","journal-title":"J Clin Oncol"},{"issue":"10","key":"660_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359. https:\/\/doi.org\/10.2165\/11535960-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"660_CR26","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645\u201368. https:\/\/doi.org\/10.1002\/jps.20178.","journal-title":"J Pharm Sci"},{"issue":"9","key":"660_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388. https:\/\/doi.org\/10.1002\/psp4.12224.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"660_CR28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/cam4.2798","volume":"9","author":"S Tokola","year":"2020","unstructured":"Tokola S, Kuitunen H, Turpeenniemi-Hujanen T, Kuittinen O. Significance of bulky mass and residual tumor\u2014treated with or without consolidative radiotherapy\u2014to the risk of relapse in DLBCL patients. Cancer Med. 2020;9(6):1966\u201377. https:\/\/doi.org\/10.1002\/cam4.2798.","journal-title":"Cancer Med"},{"issue":"4","key":"660_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5604\/01.3001.0012.0916","volume":"17","author":"JR Carvalho","year":"2018","unstructured":"Carvalho JR, Verdelho MM. New insights about albumin and liver disease. Ann Hepatol. 2018;17(4):547\u201360. https:\/\/doi.org\/10.5604\/01.3001.0012.0916.","journal-title":"Ann Hepatol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00660-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00660-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00660-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T15:03:52Z","timestamp":1646147032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00660-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00660-3","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B. Hess has had a consulting\/advisory role for ADC Therapeutics, an advisory role for Bristol-Myers Squibb and AstraZeneca, and has served on the speaker\u2019s bureau of AstraZeneca. W. Townsend has had a consulting\/advisory role for Celgene, Gilead, and Roche; served on the speaker\u2019s bureau of Celgene, Gilead, and Roche; received honoraria from Celgene, Gilead, Roche; received consulting fees from Celgene, Gilead, and Roche; received travel fees from Roche; and is supported by the National Institute for Health Research University College Hospitals Biomedical Research Centre. W. Ai has served on advisory boards for Acrotech Biopharma, ADC Therapeutics, BeiGene, Kymera Therapeutics, and Nurix Therapeutics, and received research funding from Nurix Therapeutics. A. Stathis has had a consulting role for Bayer, received research funding from AbbVie, ADC Therapeutics, Bayer, MEI Pharma, Merck, Novartis, Pfizer, and Roche, and fees for travel from AbbVie and PharmaMar. M. Solh received research funding from ADC Therapeutics and Partner Therapeutics, and served on advisory boards for Bristol-Myers Squibb, Pfizer, and Seattle Genetics, and on a speaker\u2019s bureau for Amgen and Celgene. J.P. Alderuccio was paid for expert testimony by ADC Therapeutics, OncInfo, and OncLive, and he or his immediate family member has served on advisory boards for Agios Pharmaceuticals, Forma Therapeutics, Foundation Medicine, Inovio Pharmaceuticals, and Puma Biotechnology. D. Ungar and J. Boni are employees of ADC Therapeutics and own stock in the company. X. Zhang is a former employee of ADC Therapeutics. S. Liao, L. Liao, and L. Khouri are employees of Pharmax Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}],"article-number":"11"}}